N-acetylcysteine (NAC) in the treatment of Obsessive-Compulsive Disorder (OCD)

N-acetylcysteine (NAC) in the treatment of Obsessive-Compulsive Disorder (OCD)

CONDITION

Mental Health

GENDER

Both males and females

AGE GROUP

18 years to 70 years

TRIAL STATUS

Recruiting

A 24-week, double blind placebo study investigating the effects of the amino acid ‘N-acetylcysteine’ (NAC) in Obsessive-Compulsive Disorder (OCD). This NHMRC funded study is currently enrolling participants at 3 trial sites – The University of Melbourne, University of Queensland and Western Sydney University.

Eligible participants will be randomised to receive NAC (2,000mg – 4,000mg) or placebo adjunctive to stable pharmacotherapy for a period of 6-months.

CONTACT DETAILS

Phone Number: 03) 9487 4659
Email: arcadia-research@unimelb.edu.au
Location: 2 Salisbury St, Richmond, Victoria, Australia

Butterfield St, Herston, Queensland, Australia

Campbelltown, New South Wales, Australia

CONTACT SITE

Approved By: TMC Research Ethics Committee              

Clinical Trial Registry Link: